Last reviewed · How we verify
I.V cefuroxime 750 mg*3/d for 2 days
I.V cefuroxime 750 mg*3/d for 2 days is a Second-generation cephalosporin Small molecule drug developed by Western Galilee Hospital-Nahariya. It is currently FDA-approved for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, bone and joint, meningitis, septicemia), Perioperative prophylaxis in surgical procedures.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, bone and joint, meningitis, septicemia), Perioperative prophylaxis in surgical procedures.
At a glance
| Generic name | I.V cefuroxime 750 mg*3/d for 2 days |
|---|---|
| Sponsor | Western Galilee Hospital-Nahariya |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefuroxime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of infections. The intravenous formulation allows for rapid systemic distribution and is commonly used for serious infections requiring high serum concentrations.
Approved indications
- Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, bone and joint, meningitis, septicemia)
- Perioperative prophylaxis in surgical procedures
Common side effects
- Diarrhea
- Nausea
- Phlebitis at injection site
- Hypersensitivity reactions
- Headache
- Vomiting
Key clinical trials
- Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I.V cefuroxime 750 mg*3/d for 2 days CI brief — competitive landscape report
- I.V cefuroxime 750 mg*3/d for 2 days updates RSS · CI watch RSS
- Western Galilee Hospital-Nahariya portfolio CI
Frequently asked questions about I.V cefuroxime 750 mg*3/d for 2 days
What is I.V cefuroxime 750 mg*3/d for 2 days?
How does I.V cefuroxime 750 mg*3/d for 2 days work?
What is I.V cefuroxime 750 mg*3/d for 2 days used for?
Who makes I.V cefuroxime 750 mg*3/d for 2 days?
What drug class is I.V cefuroxime 750 mg*3/d for 2 days in?
What development phase is I.V cefuroxime 750 mg*3/d for 2 days in?
What are the side effects of I.V cefuroxime 750 mg*3/d for 2 days?
What does I.V cefuroxime 750 mg*3/d for 2 days target?
Related
- Drug class: All Second-generation cephalosporin drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs)
- Manufacturer: Western Galilee Hospital-Nahariya — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, bone and joint, meningitis, septicemia)
- Indication: Drugs for Perioperative prophylaxis in surgical procedures
- Compare: I.V cefuroxime 750 mg*3/d for 2 days vs similar drugs
- Pricing: I.V cefuroxime 750 mg*3/d for 2 days cost, discount & access